Adverse drug event trigger tool: A practical methodology for measuring medication related harm

Quality and Safety in Health Care

Volumn 12, Issue 3, 2003, Pages 194-200

  Rozich, J D ^a   Haraden, C R ^b   Resar, R K ^a,b  

^a Mayo Health System   (United States)

^b INSTITUTE FOR HEALTHCARE IMPROVEMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE; DIPHENHYDRAMINE; FLUMAZENIL; GLUCOSE; HEPARIN; INDOMETACIN; MUSCLE RELAXANT AGENT; NALOXONE; SEDATIVE AGENT; THEOPHYLLINE; VITAMIN K GROUP; WARFARIN;

ALLERGY; AUTOMATION; BACTERIAL INFECTION; BIOSAFETY; BLEEDING; CLOSTRIDIUM DIFFICILE; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DIARRHEA; DRUG WITHDRAWAL; FALLING; HEALTH CARE; HOSPITAL PATIENT; HUMAN; HYPOTENSION; KIDNEY FAILURE; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; NAUSEA; PILOT STUDY; PROTHROMBIN TIME; RASH; REVIEW; SCALE UP; SEDATION; SIDE EFFECT; TECHNIQUE; VOMITING;

EID: 0037699987     PISSN: 09638172     EISSN: None     Source Type: Journal    
DOI: 10.1136/qhc.12.3.194     Document Type: Review

References (16)

1. Kohn L, Corrigan J, Donaldson M, eds. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999.
2. Richardson WC, Briere R, eds. Crossing the quality chasm: a new health system for the 21st century. Committee on Quality of Health Care in America, Institute of Medicine. Washington, DC: National Academy Press, 2001.
3. Bates DW, Boyle DL, Vander Vliet VM, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995;10:199-205.
4. Bates DW, Cullen DJ, Laird NM, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995;274:29-34.
5. Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA 1997;277:312-7.
6. Ebbesen J, Juajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med 2001;161:2317-23.
7. Leape LL, Kabcenell A, Berwick DM, et al. Reducing adverse drug events. Boston: Institute for Healthcare Improvement, 1998.
8. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events. J Am Med Informatics Assoc 1998;5:305-14.
9. Jick H, Miettinen OS, Shapiro S, et al. Comprehensive drug surveillance. JAMA 1970;213:1455-60.
10. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991;266:2847-51.
11. Classen DC, Pestotnik SL, Evans RS, et al. Using a hospital information system to assess the effects of adverse drug events. Proceedings of the Annual Symposium on Computer Applications in Medical Care 1993;161-5.
12. Classen DC, Pestotnik SL, Evans RS, et al. Description of a computerized adverse drug event monitor using a hospital information system. Hosp Pharmacy 1992;27:774, 776-9, 783.
13. Classen DC, Pestotnik SL, Scott ER, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
14. Kock K. Use of standardized screening procedures to identify adverse drug reactions. Am Soc Hosp Pharmacy 1990;47:1314-20.
15. Esch AF, Inman WH, Westerholm B. WHO Tech Rep Ser 1971;498:1-47.
16. Classen DC. Adverse drug events and medication errors: the scientific perspective. In: Scheffler AL, Zipperer LA, eds. Proceedings of enhancing patient safety and reducing errors in health care. Chicago, IL: National Patient Safety Foundations, 1999.